<DOC>
	<DOCNO>NCT01987453</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) without ribavirin ( RBV ) participants chronic genotype 1 hepatitis C virus ( HCV ) infection participate prior Gilead-sponsored HCV treatment study , achieve sustain virologic response ( SVR24 ) , define HCV RNA &lt; low limit quantification ( LLOQ ) 24 week last dose study drug ( SVR24 ) .</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination Â± Ribavirin Participants With Chronic Genotype 1 HCV Who Participated Prior Gilead-Sponsored HCV Treatment Study</brief_title>
	<detailed_description />
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Key Willing able provide write informed consent Infection HCV genotype 1 HCV RNA &gt; LLOQ screen Participation prior Gileadsponsored study Screening laboratory value within define threshold Use two effective contraception method female childbearing potential sexually active male Must generally good health , exception chronic HCV infection , determine Investigator Must able comply dose instruction study drug administration able complete study schedule assessment Key Pregnant nurse female male pregnant female partner Coinfection HIV hepatitis B virus ( HBV ) Current prior history clinical hepatic decompensation ( Groups 1 2 ) Hepatocellular carcinoma ( HCC ) History clinically significant illness medical disorder may interfere subject treatment , assessment compliance protocol Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>genotype 1</keyword>
</DOC>